ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD.

Zhejiang Hisoar Pharmaceutical Co., Ltd.

002099

CNE000001PY2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 30/05/2024 am IST			5-day change	1st Jan Change
5.84 ^CNY	+0.34%		-2.50%	-18.78%

06/05	Tranche Update on Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.	CI
01/05	Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 3, 2024, has closed with 31,478,531 shares, representing 1.95% for CNY 151.42 million.	CI

Zhejiang Hisoar Pharmaceutical Co., Ltd. Approves Board Appointments

October 12, 2012

Zhejiang Hisoar Pharmaceutical Co., Ltd. announced at EGM held on October 11, 2012, the shareholders of the company approved election of Bei Nianjiao and Shen Lihua as directors.

Latest news about Zhejiang Hisoar Pharmaceutical Co., Ltd.

Tranche Update on Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.	06/05	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 3, 2024, has closed with 31,478,531 shares, representing 1.95% for CNY 151.42 million.	01/05	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	28/04	CI
Hisoar Pharma's Unit Passes German Health Regulator's Inspection	18/04	MT
Tranche Update on Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.	01/04	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.	02/02	CI
Hisoar Pharma Chairman Plans Up to 20 Million Yuan Investment	02/02	MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	02/02	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Zhejiang Hisoar Pharma Passes Good Manufacturing Practice Compliance Inspection	22/23/22	MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Zhejiang Hisoar Pharma Registers New Drug For Diabetes Patients	11/23/11	MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 24 May 2023	20/23/20	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Approves the Profit Distribution Proposal for 2022	17/23/17	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for 2022	26/23/26	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/23/24	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Elects Tao Hong as Non-Independent Director; and Yu Yongping, Qian Jianmin and Liang Chao as Independent Directors	02/22/02	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/22/30	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22/22/22	CI
Hainan Visum Pharmaceutical Co Ltd announced that it has received $15 million in funding from Zhejiang Hisoar Pharmaceutical Co., Ltd.	29/22/29	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 25 May 2022	19/22/19	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Approves Dividend for 2021	17/22/17	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	26/22/26	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	25/22/25	CI

Chart Zhejiang Hisoar Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Hisoar Pharmaceutical Co., Ltd.

More charts

ZHEJIANG HISOAR PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the manufacture and sale of pharmaceutical materials and dyes. The Company operates through two segments: Pharmaceutical segment and Dye segment. Pharmaceutical segment manufactures and sells Active Pharmaceutical Ingredients (APIs) and preparations, as well as provides customized production and supporting research and development services for international pharmaceutical companies. The Companyâs pharmaceutical products comprise antibiotic series, hypoglycemic series and cardiovascular series. Dye segment is mainly involved in the manufacture and sale of environmentally friendly reactive dyes, dye intermediates and pigment intermediates. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD.	-18.78%	1.29B
ELI LILLY AND COMPANY	+39.82%	734B
NOVO NORDISK A/S	+31.92%	591B
JOHNSON & JOHNSON	-7.31%	350B
MERCK & CO., INC.	+14.23%	315B
ABBVIE INC.	+0.86%	276B
ASTRAZENECA PLC	+13.87%	238B
ROCHE HOLDING AG	-6.34%	204B
NOVARTIS AG	+8.38%	206B
AMGEN INC.	+4.51%	161B

Other Pharmaceuticals